Can AI uncover a new path to non-opioid pain relief? As non-opioid pain therapies continue to face setbacks, Insilico is using AI to uncover new biology and therapeutic targets. Written byBree Foster, PhD

Can AI uncover a new path to non-opioid pain relief? As non-opioid pain therapies continue to face setbacks, Insilico is using AI to uncover new biology and therapeutic targets. Written byBree Foster, PhD https://www.drugdiscoverynews.com/can-ai-uncover-a-new-path-to-non-opioid-pain-relief-17425 The search for effective non-opioid pain medicines has produced both breakthroughs and setbacks. While the approval of Vertex Pharmaceuticals’ non-opioid drug Journavx in 2025 offered a new option for acute pain, it didn’t see the immediate commercial success many analysts anticipated, with third-quarter sales falling $3 million short of expectations. This was quickly followed by Vertex then discontinuing a follow-up non-opioid candidate after disappointing clinical results. Meanwhile, Eli Lilly has shelved two non-opioid drug candidates.